<DOC>
	<DOCNO>NCT01170962</DOCNO>
	<brief_summary>The purpose study determine whether BMS-790052 add Peginterferon Alfa-2a ribavirin result high cure rate patient previously fail therapy may limit response retreatment Peginterferon Alfa-2a ribavirin alone .</brief_summary>
	<brief_title>Study Anti-HCV Drug ( BMS-790052 ) Combined With Peginterferon Ribavirin Patients Who Failed Prior Treatment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects chronically infect HCV genotype 1 Nonresponder prior therapy peginterferon alfa ribavirin HCV RNA viral load 100,00 IU/mL Results liver biopsy â‰¤ 24 month prior randomization consistent chronic HCV infection ; compensate cirrhotics time prior randomization ( compensate cirrhotics biopsy enrollment cap 25 % randomize study population ) Ultrasound , CT scan MRI result 12 month prior randomization demonstrate hepatocellular carcinoma Body Mass Index ( BMI ) 18 35 kg/m2 Positive Hepatitis B infection ( HBsAg ) HIV1/HIV2 antibody screen Evidence medical condition associate chronic liver disease HCV Evidence decompensated cirrhosis base radiologic criterion biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>